Our
News
Check back on a regualr basis
for futher updates.
NG11-2 Phase-Ib Dose Escalation Clinical Study Progresses to Final Dose Level
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
VasoDynamics files global patent (PCT) for the methods to select patients for the clinical studies on radiation-induced oral mucositis
Platform products Intellectual Property protection extended to 2043
NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
VasoDynamics strengthens management team with key appointments
Building a strong team of industry experts as clinical programmes progress.
First dose cohort completed and enrolment to second dose cohort commenced in NG11-2 Phase-Ib clinical trial
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
First patient dosed for the first week in NG11-2 Phase Ib clinical trial
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
